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Research in movement disorders in 2012 has improved our understanding of the pathogenic mechanisms of disease and led to development of potential novel therapeutic approaches. Key advances were linked to mechanisms underlying spread of neurodegenerative pathology, immunotherapy, stem cells, genetics and deep brain stimulation in parkinsonism and related disorders. Despite recent advances in our understanding of the pathogenesis and treatment of movement disorders such as Parkinson disease (PD), many of these syndromes remain challenging to diagnose and to treat. Moreover, disease-modifying therapies remain elusive. Continued progress in elucidating the pathophysiology of these dis orders and translation of research from bench to bedside will result in better diagnostics and development of novel thera peutics. Research in 2012 has moved the field closer to this goal, and important progress had been made in numerous areas, including basic and clinical work in parkinsonism, dystonia, Huntington disease (HD), essential tremor, and tic disorders. We highlight some of the recent and key advances in each area that are collectively leading to improved understanding of basic pathophysiology and novel approaches to therapy.
A major hallmark of PD and related disorders is the presence of Lewy body pathology, with concomitant neurodegeneration linked to abnormal accumulation and deposition of α-synuclein. Mounting evidence supports the hypothesis of prion-like spread of pathology via cell-to-cell transmission of pathological forms of proteins such as α-synuclein. 1 Unanswered questions remain, however, about the mode of transmission of pathological α-synuclein species and their role in disease pathogenesis.
Building on previous work demonstrating the ability of preformed α-synuclein fibrils to precipitate Lewy body-like pathology and neurodegeneration, Luk and colleagues recently showed that intracerebral injections of exogenous preformed fibrils or brain homogenates from old, symptomatic Ala53Thr transgenic mice (which express Ala53Thr human α-synuclein) into younger, asymptomatic mice could accelerate Lewy pathology. 2 In the inoculated animals, widespread α-synuclein pathology-including misfolded and hyperphosphorylated α-synuclein and intracellular Lewy-like inclusions-was observed, with a resultant decrease in survival of these animals. The findings provide further evidence of prionlike spread and propagation of synucleinopathy, and cell-to-cell transmission of pathological proteins. Furthermore, exogenous preformed α-synuclein fibrils were sufficient to produce this cascade of events and accelerate the disease phenotype in vivo. On the basis of these findings, targeting of cell-to-cell transmission to block the spread of synucleinopathy is a promising therapeut ic approach to disorders such as PD.
Evidence points to an important role for release of extracellular α-synuclein from neurons in the transmission of pathology. Approaches such as passive and active immunization to target α-synuclein have shown promise in synucleinopathy models, with reduction in α-synuclein accumulation and associated neuro degeneration. 3, 4 The exact mechanism of action, however, remains unclear. In a study published in The Journal of Neuroscience, Bae et al. hypothesized that antibodies against α-synuclein target extracellular α-synuclein and aid microglia in the clearance of pathological protein species, thereby preventing cell-to-cell propagation of pathology. 5 The researchers showed that α-synuclein antibodies bound to extracellular aggregates are taken up by microglia through surface Fcγ receptors, and are then delivered to microglial lysosomes for degradation. Intracerebral injection of α-synuclein antibody in a transgenic mouse model also resulted in α-synuclein clearance, and specifically reduced neuronto-astroglia transmission of the protein, promoting microglial uptake and removal of extracellular α-synuclein. These studies help to further elucidate the mechanism of cell-to-cell transmission of α-synuclein, and highlight a potential immunotherapy for PD and related disorders.
Advances in other synucleinopathies such multiple system atrophy (MSA)-a disorder in which standard PD therapies often fail -have also been made. Following an initial open-label trial of autologous mesenchymal stem cells (MSCs) in MSA that attracted criticism from researchers in the field but also provided hope for a novel therapy, Lee et al. reported the results of a 1-year random ized clinical trial. 6 The therapeutic mechanism NATURE REVIEWS | NEUROLOGY VOLUME 9 | FEBRUARY 2013 | 71
YEAR IN REVIEW
of MSCs in neurodegenerative disease is debated, but these cells are known to be capable of differentiating into various cell types under specific conditions, and also of secreting potentially neuro protective trophic factors. In this study, vehicle or MSCs were administered to patients intra-arterially followed by thrice-monthly intravenous infusions of the cells. 27 of the 33 enrolled patients with MSA completed the study, and all participants demonstrated delayed progression on the Unified MSA Rating Scale (UMSARS). However, no difference was observed in the UMSARS daily living scores between the two groups, indicating that the treatment predominant ly affected motor deficits. Secondary outcomes, including functional (PET) and structural (MRI) brain imaging, also indicated beneficial effects of MSC therapy. 6 Although encouraging, this study had several limitations. It was performed in a single centre and included only patients with cerebellar-predominant MSA, which prevents extrapolation to parkinsonismpredominant MSA-a form of MSA that is more-frequently encountered by physicians in the USA, Canada and Europe. Importantly, one-third of patients who received either vehicle or MSCs had ischaemic lesions on MRI, raising the issue of interventionassociated risks. The transiency of the therapeutic effects, however, indicated the need for repeated administration. Although these major concerns must be resolved for future application of MSCs in clinical practice, this study clearly highlights a potential novel therapeutic approach to MSA, and possibly to other neurodegenerative disorders.
Induced pluripotent stem cells (iPSCs) have potential to become a powerful therapy for neurodegenerative diseases. Patientderived iPSCs provide a source of stem cells for autologous transplantation and avoid the risk of rejection associated with allogenic transplants. The main drawback of this therapy is that patient-derived stem cells harbour the disease-causing mutation. An et al. performed a proof-of-concept experiment in which the CAG repeat expansion that causes HD was corrected in patientderived iPSCs. 7 Fibroblasts isolated from patients with HD were reprogrammed into iPSCs, and the HD repeat expansion was corrected by insertion of a normal copy of the Huntingtin gene and stimulation of homologous recombination.
The molecular phenotypes associated with HD-including defects in apoptosis, cell signalling and bio energetics, and abnormal levels of brain-derived neuro trophic factor-were reversed in the genome-corrected cells, but remained in the uncorrected iPSCs. 7 Importantly, the genome-corrected iPSCs retained pluripotency, differentiating not only into neural stem cells but also into stria tal neurons in vitro and in vivo. Strikingly, when transplanted into the striatum of the R6/2 mouse model of HD, neural stem cells derived from the genome-corrected iPSCs populated the striatum and differentiated into γ-aminobutyric acid-releasing medium spiny neurons and astrocytes. Whether the iPSCs could reverse the behavioural deficits and early lethality seen in the R6/2 mouse was not reported. This study highlights the utility and feasibility of patient-derived iPSCs as a future therapeutic option and has farreaching implications not only for HD, but also for all neurodegenerative disorders that are underpinned by a known gene mutation.
Deep brain stimulation has revolutionized therapy for PD and dystonia, and is being increasingly considered for use in other conditions such as Tourette syndrome. In a recent study, patients with highly medically resistant Tourette syndrome were implanted with centromedian thalamic deep brain stimu lation electrodes. In a series of studies, the investigators showed that scheduled rather than chronic stimulation may suppress tics. 8 More importantly, however, was the observation of a clinical correlation between the presence of γ-band activity and decreased tic severity. Temporal correlation between the power of γ-band activity and tic suppression was evident. In PD, β-band activity has emerged as an important physiological marker of disease. 9 In Tourette syndrome, modulation of γ-band activity could be critic al to the success of new therapeutics. 9, 10 Together, the advances highlighted here demonstrate continued progress in understanding the pathological mechanisms of movement disorders and the critical nature of these findings in developing novel therapeutics. Translation of basic findings into new approaches to target these diseases will be essential to advance future therapies.
